Mnemo Therapeutics locks in Series A
Mnemo Therapeutics, a provider of epigenetic antigens, stronger T cells, has raised 75 million euros in Series A funding.
Mnemo Therapeutics, a provider of epigenetic antigens, stronger T cells, has raised 75 million euros in Series A funding.